Highlights 

  • New pooled analysis shows Yescarta delivers dependable outcomes across transplant-eligible and ineligible R/R LBCL patients 
  • Combined data from ZUMA-7 and ALYCANTE reinforce its role as a one-time, curative-intent therapy 
  • Two-year overall survival in pooled data reached 64.9%, far surpassing historical outcomes 
  • Safety profile remained aligned between both trials despite differing patient complexities 
  • Quality of life improvements continued for two years post-treatment 

Gilead Sciences (NASDAQ:GILD), through its Kitesubsidiary, presented new data reinforcing the performance and consistency of its CAR T-cell therapy, Yescarta, in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). The analysis combined four-year outcomes from the Phase 3 ZUMA-7 trial and two-year findings from the Phase 2 ALYCANTE study, which focused on patient's ineligible for standard high-dose chemotherapy and autologous stem cell transplant (ASCT). 

The pooled dataset included 247 patients and demonstrated encouraging outcomes, regardless of transplant eligibility. Two-year overall survival reached 64.9% in the combined analysis, compared to historical survival rates of roughly 20% before CAR T therapies became available. Event-free survival and progression-free survival in the pooled results came in at 45.2% and 47.4%, respectively, showing durability across both patient groups. 

Furthermore, after three months, 55.6% of patients achieved a complete metabolic response, an important indicator of minimal detectable disease. At one year, the overall response rate held at 46.6%, and among responders, 61% maintained their response for at least twelve months. 

Safety Remains Consistent Across Diverse Patient Profiles 

The safety evaluation, based on 232 Yescarta-treated patients across both trials, showed comparable outcomes between ZUMA-7 and ALYCANTE despite ALYCANTE enrolling older and more medically complex patients. Grade ≥3 treatment-emergent adverse events were reported at a pooled rate of 90.5%. 

Grade ≥3 neurologic events were observed in 19.8% of patients across the pooled analysis, with ZUMA-7 reporting 21.2% and ALYCANTE reporting 16.1%. Hematologic adverse events, including neutropenia and anemia, were also closely aligned. This consistency reinforces Yescarta’s profile even in real-world settings involving patients not suited for intensive chemotherapy or transplant procedures. 

Quality of Life Gains Highlight Long-Term Benefits 

Both studies reported significant quality-of-life recovery trends following initial post-infusion challenges. While patients experienced temporary declines in health status by Day 50, meaningful improvements were recorded by Day 100 in ALYCANTE and Day 150 in ZUMA-7. These gains continued through Month 12 and remained evident up to Month 24, suggesting that Yescarta’s therapeutic impact extends beyond clinical metrics and into daily well-being. 

Conclusion 

The new pooled analysis underscores the consistency and long-term promise of Yescarta as a second-line treatment option for R/R LBCL. By delivering encouraging survival outcomes, comparable safety results, and meaningful quality-of-life improvements, the therapy continues to shift treatment paradigms for patients who previously had limited choices. 

Gilead Sciences’ shares closed at USD 121.22, marking a 1.14% increase from the prior session.